Lymphoma Panel (outsource Genetech) at Chughtai Lab

Lymphoma Panel (outsource Genetech) at Chughtai Lab

The Lymphoma Panel (outsource Genetech) at Chughtai Lab is a highly specialized, state-of-the-art molecular and immunophenotypic diagnostic profile. This comprehensive panel is designed to detect, classify, and monitor various forms of lymphatic malignancies, including Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). By partnering with Genetech, a premier molecular genetics laboratory, Chughtai Lab provides patients and oncologists across Pakistan, including major hubs like Lahore, Karachi, and Islamabad, with access to world-class diagnostic precision. Lymphomas are highly heterogeneous cancers of the lymphatic system, comprising over 90 distinct subtypes. Accurate classification is critical because the therapeutic approach, prognosis, and eligibility for targeted therapies vary dramatically based on the specific molecular and genetic profile of the tumor. This panel utilizes advanced diagnostic technologies, including polymerase chain reaction (PCR), flow cytometry, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), to analyze cellular markers and genetic rearrangements.

Understanding the underlying biology of lymphatic clonal expansions is the cornerstone of modern hematooncology. The Lymphoma Panel evaluates specific cellular lineages (B-cell or T-cell), assesses clonality, and identifies characteristic chromosomal translocations. This high-level diagnostic value helps clinicians differentiate between reactive lymphoid hyperplasia (a benign inflammatory response) and true malignant lymphoma. Furthermore, the integration of Genetech’s specialized molecular testing ensures that even the rarest genetic mutations and translocations are detected with high sensitivity and specificity. For patients undergoing diagnostic workups for unexplained lymphadenopathy, systemic symptoms, or abnormal hematological findings, this panel offers a definitive pathway to an accurate diagnosis, enabling the formulation of highly personalized treatment strategies.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure specimen integrity and accurate diagnostic results. Depending on the specimen type required by your physician (peripheral blood, bone marrow aspirate, or tissue biopsy), the following preparation guidelines should be followed:

• Clinical Documentation: Patients must provide a complete clinical history, previous complete blood count (CBC) reports, and any prior histopathology or flow cytometry reports.
• Tissue Specimens: If submitting a formalin-fixed paraffin-embedded (FFPE) tissue block or biopsy slides, the original pathology report must accompany the sample. The tissue must be fixed properly to prevent degradation of nucleic acids.
• Medication History: Inform your physician and the laboratory staff of all ongoing medications, especially immunosuppressants, chemotherapy, or corticosteroids, as these can alter cellular markers.
• Fasting Requirements: Routine fasting is generally not required for peripheral blood collection. However, if bone marrow aspiration is scheduled under sedation, fasting instructions provided by the clinical team must be strictly followed.
• Hydration: Adequate hydration is recommended prior to peripheral blood collection to facilitate easier venous access.

During the Procedure

The collection process depends entirely on the sample type prescribed by your oncologist:

• Peripheral Blood Collection: A phlebotomist will locate a suitable vein in your arm, cleanse the area with an antiseptic, and draw a specific volume of blood into specialized collection tubes (typically EDTA or heparin tubes). The process takes less than five minutes and involves minimal discomfort.
• Bone Marrow Aspiration and Biopsy: This procedure is performed by a qualified hematologist or oncologist in a clinical setting. The patient lies on their side or stomach. Local anesthesia is applied to the hip bone area. A specialized needle is used to collect a small sample of liquid bone marrow (aspirate) and a small core of bone tissue (biopsy).
• Tissue Biopsy Submission: For patients who have already undergone a surgical lymph node biopsy, the preserved tissue block is safely received, logged, and prepared for transport to the molecular testing facility under strict temperature-controlled conditions.
• Safety and Comfort: All procedures are conducted using sterile, single-use equipment to eliminate any risk of infection. Experienced staff ensure patient comfort throughout the specimen collection process.

When is a Lymphoma Panel Performed?

Diagnosis of Unexplained Lymphadenopathy

Physicians request a Lymphoma Panel when a patient presents with persistent, unexplained swelling of the lymph nodes (lymphadenopathy) in the neck, armpits, or groin. When these swollen nodes are painless, firm, and do not regress over several weeks, it raises clinical suspicion for malignancy. The panel helps distinguish benign, reactive lymph node enlargement caused by infections from clonal, malignant expansions of lymphoid cells.

Differentiation Between Hodgkin and Non-Hodgkin Lymphoma

Accurate differentiation between Hodgkin Lymphoma and Non-Hodgkin Lymphoma is a primary clinical indication for this test. Because these two categories of lymphatic cancer require entirely different chemotherapy regimens and therapeutic protocols, identifying the presence of classic Reed-Sternberg cells or specific B-cell and T-cell surface antigens is critical for establishing the correct therapeutic pathway.

Evaluation of Systemic B-Symptoms

The presence of systemic symptoms, clinically referred to as “B-symptoms”—which include unexplained fever, drenching night sweats, and significant unintentional weight loss (more than 10% of body weight within six months)—strongly warrants a comprehensive diagnostic workup. A Lymphoma Panel is performed to investigate whether these systemic manifestations are driven by an underlying clonal lymphatic malignancy.

Assessment of Minimal Residual Disease (MRD)

During or after the completion of chemotherapy, immunotherapy, or stem cell transplantation, physicians utilize this highly sensitive panel to detect Minimal Residual Disease (MRD). MRD refers to the small number of cancer cells that remain in the body during or after treatment. Detecting these cells at a molecular level helps clinicians assess treatment efficacy, predict potential relapse, and decide whether further consolidation therapy is required.

Identification of Prognostic Genetic Markers

The Lymphoma Panel is performed to identify specific genetic translocations and mutations that carry prognostic significance. For instance, identifying “double-hit” or “triple-hit” lymphomas (characterized by rearrangements in the MYC, BCL2, and/or BCL6 genes) alerts oncologists to highly aggressive disease forms that require intensive, specialized treatment protocols rather than standard chemotherapy.

What Does a Lymphoma Panel Detect?

The Lymphoma Panel (outsource Genetech) at Chughtai Lab evaluates a wide array of molecular, genetic, and immunophenotypic markers to provide a comprehensive diagnostic profile. The panel is capable of detecting:

• Clonal Immunoglobulin Heavy Chain (IGH) Gene Rearrangements: Confirms the presence of a clonal (monoclonal) B-cell population, indicating B-cell lymphoma.
• Clonal T-Cell Receptor (TCR) Gene Rearrangements: Identifies clonal T-cell populations, confirming T-cell lineage malignancies.
• t(14;18) Translocation (BCL2/IGH): A genetic hallmark highly associated with Follicular Lymphoma and some cases of Diffuse Large B-Cell Lymphoma (DLBCL).
• t(11;14) Translocation (CCND1/IGH): The diagnostic marker for Mantle Cell Lymphoma, leading to the overexpression of Cyclin D1.
• t(8;14) Translocation (MYC/IGH): The characteristic genetic translocation diagnostic of Burkitt Lymphoma.
• ALK Gene Rearrangements: Evaluates the presence of Anaplastic Lymphoma Kinase gene fusions, crucial for subtyping Anaplastic Large Cell Lymphoma.
• CD19 and CD20 Expression: Confirms B-cell lineage and determines eligibility for targeted anti-CD20 monoclonal antibody therapies like rituximab.
• CD3 and CD5 Expression: Evaluates T-cell lineage markers and detects aberrant expression patterns.
• CD10 Expression: A marker for germinal center B-cells, useful in subtyping Diffuse Large B-Cell Lymphoma.
• CD23 and CD5 Co-expression: Helps differentiate Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) from Mantle Cell Lymphoma.
• CD30 Expression: Highly expressed in Reed-Sternberg cells of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma; guides targeted brentuximab vedotin therapy.
• CD45 (Leukocyte Common Antigen) Expression: Confirms the hematopoietic origin of the tumor cells, differentiating them from metastatic carcinomas.
• Monoclonality of Kappa or Lambda Light Chains: Detects restricted light chain expression, a definitive indicator of B-cell malignancy.
• TP53 Gene Mutations: Identifies high-risk genetic alterations associated with chemotherapy resistance and poor prognosis.
• BRAF V600E Mutation: A highly specific molecular marker for Hairy Cell Leukemia.
• MYD88 L265P Mutation: Highly diagnostic for Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia.
• BCL6 Gene Rearrangements: Assesses translocations involving the BCL6 locus on chromosome 3q27, common in diffuse large B-cell lymphomas.
• Ki-67 Proliferation Index: Measures the percentage of actively dividing tumor cells, indicating the growth rate and aggressiveness of the lymphoma.
• EBER (EBV-encoded RNA): Detects the presence of Epstein-Barr Virus within lymphoid cells, associated with specific lymphoma subtypes.
• SOX11 Expression: A valuable diagnostic marker for Cyclin D1-negative Mantle Cell Lymphoma.

Turnaround Time and Report Access at Chughtai Lab

Because the Lymphoma Panel involves highly specialized molecular and genetic testing outsourced to Genetech’s advanced laboratory, the processing and analysis of these complex specimens require meticulous quality control. The turnaround time (TAT) for this panel is typically 10 to 14 working days. This duration ensures that DNA/RNA extraction, PCR amplification, gene sequencing, and expert pathological correlations are executed with absolute precision.

Chughtai Lab offers seamless digital access to diagnostic reports. Once the specialized results are finalized and verified by consultant pathologists, patients and their referring oncologists receive an automated SMS notification. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website or via the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any Chughtai Lab diagnostic center across Pakistan.

Lymphoma Panel Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
B-Cell Clonality (IGH)	Polyclonal (diverse) B-cell population	Monoclonal (clonal) IGH gene rearrangement
T-Cell Clonality (TCR)	Polyclonal (diverse) T-cell population	Monoclonal (clonal) TCR gene rearrangement
t(14;18) BCL2/IGH	Negative (No translocation detected)	Positive (Associated with Follicular Lymphoma)
t(11;14) CCND1/IGH	Negative (No translocation detected)	Positive (Diagnostic for Mantle Cell Lymphoma)
t(8;14) MYC/IGH	Negative (No translocation detected)	Positive (Diagnostic for Burkitt Lymphoma)
Light Chain Restriction	Balanced Kappa and Lambda ratio	Monoclonal restriction (Kappa or Lambda excess)
Ki-67 Proliferation Index	Low physiological proliferation (varies by tissue)	Elevated index (e.g., >90% in Burkitt Lymphoma)
MYD88 L265P Mutation	Wild-type (No mutation detected)	Mutant detected (Indicates Waldenström Macroglobulinemia)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Lymphoma Panel?

• Strategic Collaboration: Partnering with Genetech ensures access to cutting-edge molecular diagnostics and advanced genetic sequencing.
• Expert Pathologists: Reports are reviewed and interpreted by highly experienced hematopathologists and molecular biologists.
• Nationwide Network: Convenient sample collection facilities across Pakistan, including Lahore, Karachi, and Islamabad.
• Strict Cold Chain Management: Specialized transport protocols ensure the integrity of molecular and tissue specimens during transit.
• Comprehensive Diagnostic Menu: Chughtai Lab offers integrated pathology, radiology, and molecular services under one roof.
• International Quality Standards: Strict adherence to rigorous quality control and external quality assurance programs.
• Digital Convenience: Easy online report access through the Chughtai Lab mobile application and web portal.
• Patient-Centric Care: Dedicated support desk to assist patients with complex molecular testing requirements and scheduling.